Donate Now

Clinical Trials

Interventional Clinical Trials

Please click on table and use scroll bars at bottom and right side of table to navigate . Last updated on: 23 January 2026. iMyoS will not be held responsible for any inaccuracies. This list serves as a guidance for interventional clinical trials, for latest details, and all other type of studies, please refer to clinicaltrials.gov.

Trial identifier ( Click to clinicaltrials.gov )Name of Drug/(Study Name)Type of Drug Route of administration Sponsor/Collaborator (study website link if available)LocationsStudy StatusIndicationsAgeEmail contact addressPhaseEnrollmentStart DatePrimary Completion DateCompletion Date
NCT06698796Dazukibart PF-06823859IFN beta blockerIV infusionPfizerInternationalRECRUITINGDM, PMADULT, OLDER_ADULTClinicalTrials.gov_Inquiries@pfizer.com32112025-01-222027-11-252027-11-25
NCT05895786Dazukibart PF-06823859IFN beta blockerIV infusionPfizerInternationalRECRUITINGDM, PMADULT, OLDER_ADULTClinicalTrials.gov_Inquiries@pfizer.com33182023-05-202027-07-282027-07-28
NCT06455449Anifrolumab (JASMINE)IFN alpha and beta blockerSubcutaneous InjectionAstraZenecaInternationalRECRUITINGPM, DMADULT, OLDER_ADULTinformation.center@astrazeneca.com32402024-06-202027-05-142028-08-04
NCT06450886Ulviprubart/ABC008Humanized IgG1 mAb targeting KLRG1+ Tcell Subcutaneous injection Abcuro, Inc.INTERNATIONALACTIVE_NOT RECRUITINGIBMADULT, OLDER_ADULTGeneral Inquiries
corporate.contact@abcuro.com		2/32702024-10-212029-012029-04
NCT05721573Ulviprubart/ABC008Humanized IgG1 mAb targeting KLRG1+ Tcell Subcutaneous injection Abcuro, Inc./Syneos HealthINTERNATIONALACTIVE_NOT RECRUITINGIBMADULT, OLDER_ADULTGeneral Inquiries
corporate.contact@abcuro.com		2/32312023-02-282025-11-062026-01
NCT04789070SirolimusmTOR inhibitorOral TabletUniversity of Kansas Medical Center/The Perron InstituteAUS, NL, USAACTIVE_NOT RECRUITINGIBMADULT, OLDER_ADULTAustralia contact31402022-07-012027-122027-12
NCT05523167Efgartigimod PH20 SC (ALKIVIA)FcRn inhibitorSubcutaneous injection argenxINTERNATIONALACTIVE_NOT RECRUITINGDM, IMNM, PM, AsysADULT, OLDER_ADULTClinicalTrials@argenx.com 2/32652022-10-122026-12-012027-02-01
NCT05379634Nipocalimab (SPIREA)FcRn inhibitorIV infusionJanssen Research & Development, LLCINTERNATIONALACTIVE_NOT RECRUITINGDM, IMNM, PM, AsysADULT, OLDER_ADULThttps://www.jnj.com/innovativemedicine/contact-us2362022-07-052025-09-042026-09-16
NCT06371417RAY121 (RAINBOW)C1s inhibitorSubcutaneous injection Chugai PharmaceuticalsINTERNATIONALRECRUITINGAPS, BP, BS, DM, IMNM, ITPADULT, OLDER_ADULTclinical-trials@chugai-pharm.co.jp11442024-08-192026-06-302026-06-30
NCT06284954Empasiprubart ARGX-117 (EMPACIFIC)C2 inhibitorIV infusionargenxUSAACTIVE_NOT RECRUITINGDMADULT, OLDER_ADULTClinicalTrials@argenx.com 232024-08-202026-112026-11
NCT06887738NM8074 ( Ruxoprubart )C3b blockerIV infusionNovelMed Therapeuticsn/aNOT YET RECRUITINGDMADULT, OLDER_ADULTclinicalsae@novelmed.com282026-062027-112028-12
NCT06479863Pozelimab/CemdisiranC5 inhibitor/anti-C5 siRNASubcutaneous InjectionAustin Neuromuscular Center/Regeneron PharmaceuticalsUSARECRUITINGIBMADULT, OLDER_ADULTclinicaltrials@regeneron.com1102024-08-082027-05-302027-08-30
NCT06857240Ruxolitinib Topical CreamJAK 1/2 InhibitorTopical creamAnthony Fernandez, MD, PhD, The Cleveland Clinic USARECRUITINGDMADULT, OLDER_ADULTdermatologyresearch@ccf.org2152025-06-012026-122027-12
NCT06536166Ruxolitinib (BIGTIM)JAK 1/2 InhibitorOral TabletAssistance Publique - Hôpitaux de ParisFranceRECRUITINGIBMADULT, OLDER_ADULTfrancois-jerome.authier@aphp.fr2/3802025-05-272028-06-102028-09-10
NCT05524311
Baricitinib (MYOCIT)JAK 1/2 InhibitorOral TabletAssistance Publique - Hôpitaux de Paris/URC-CIC Paris Descartes Necker CochinFranceRECRUITINGJDMCHILDbrigitte.bader-meunier@aphp.fr
laure.choupeaux@aphp.fr		2162022-11-102026-052026-09
NCT04972760Baricitinib (BIRD)JAK 1/2 InhibitorOral TabletAssistance Publique - Hôpitaux de ParisFranceRECRUITINGDMADULT, OLDER_ADULTyves.allenbach@aphp.fr
sarra.pochon@aphp.fr		3622022-08-312026-02-282026-02-28
NCT06285539Filgotinib (DRIMID)JAK 1 InhibitorOral TabletUMC Utrecht/Alfasigma S.p.A.+ReumaNederland + Autoimmune Research and Collaboration HubThe NetherlandsRECRUITINGIIM, Behcet's, IG4 RDADULT, OLDER_ADULTa.c.a.marijnissen@umcutrecht.nl2602024-03-122026-122026-12
NCT05799755Nintedanib (MINT)TYK inhibitorOral TabletRohit Aggarwal, MD/Boehringer IngelheimUSAACTIVE_NOT RECRUITINGMA-ILDADULT, OLDER_ADULThttps://www.boehringer-ingelheim.com/contact-us4702023-08-012025-12-312026-06-30
NCT05695950GLPG3667 (GALARISSO)TYK2 inhibitorOral TabletGalapagos NVINTERNATIONALACTIVE_NOT RECRUITINGDMADULT, OLDER_ADULThttps://www.glpg.com/contact/2402023-02-272025-10-132026-04
NCT05437263Brepocitinib (VALOR)TYK2 /JAK1 inhibitorOral TabletPriovant Therapeutics, Inc.n/aACTIVE_NOT RECRUITINGDMADULT, OLDER_ADULThttps://priovant.com/contact.html32412022-10-312025-07-172026-07
NCT07103746Ublituximab Briumvi™️
(SUMMIT)		Anti-CD20 B cell therapyIV infusionNational Institute of Allergy and Infectious Diseases (NIAID)/Autoimmunity Centers of Excellence|TG Therapeutics|Rho Federal Systems Division, Inc.USANOT YET RECRUITINGAutoimmune DisordersADULT, OLDER_ADULThttps://www.niaid.nih.gov/2302026-012029-062030-06
NCT03816345Nivolumab (AIM-NIVO)PD-1 BlockerIV infusionNational Cancer Institute (NCI)CA/USARECRUITINGDM & other Autoimmune diseases with Hematopoietic/ Lymphoid Cell or Malignant Solid NeoplasmsADULT, OLDER_ADULTNCI 13002019-07-162028-03-302028-03-30
NCT06672822Sodium Thiosulphate AntidoteIntralesional injectionRobyn T. Domsic, MD, MPH, University of PittsburghUSARECRUITINGCalcinosis in DM, SSc, MCTDADULT, OLDER_ADULTlaffoonm@pitt.edu2202025-03-172028-08-312029-05-01
NCT03582800Sodium Thiosulphate (ITS-PILOT)AntidoteIntralesional injectionUniversity Hospital, LimogesFranceRECRUITINGCalcinosis in DM, SSc, iPPSD2CHILD, ADULT, OLDER_ADULTvincent.guigonis@unilim.fr, claire.bahans@chu-limoges.fr2402020-01-062027-06-062027-06-06
NCT07111065Omega-3 fatty acid supplements from fish oil + healthy diet (FAST)Supplements/DietOral CapsulesNational Institute of Environmental Health Sciences (NIEHS)USANOT YET RECRUITINGDMADULTccopr@nih.gov, fastdmsupport@nih.gov23002026-01-282030-11-032031-11-03
NCT06968819Zebris treadmill, Alfa stabilometric platform, Diego robotic setVirtual Reality and RoboticsVR and RoboticsNational Institute of Geriatrics, Rheumatology and Rehabilitation, PolandPolandRECRUITINGIMNM, IBMADULT, OLDER_ADULTaxmarkowska@gmail.com
beata.tarnacka@wum.edu.pl
n/a402025-02-112026-122026-12
NCT06919380MSC-exos-P1 + SOC corticosteroids/DMARDsNebulized mesenchymal stem cell-derived exosomes (MSC-exos-P1)Inhaled nebulised Guangzhou Medical UniversityChinaRECRUITINGanti-MDA5 RP-ILD DMADULT, OLDER_ADULTdrkwok@126.com1102025-04-152026-12-312027-05-31
NCT07160205ULSC (IIMPACT)Umbilical cord lining-derived stem cellIV infusionRestem, LLC.USANOT YET RECRUITINGPM, DMADULT, OLDER_ADULTSee contacts by locations on clinicaltrials.gov2/3402025-122028-082029-07
NCT06991114AlloNK® Allogeneic NK Cells + conditioning regimen + RituximabAllogenic cord blood-derived NK cellsIV infusionArtiva Biotherapeutics, Inc.InternationalRECRUITINGRA, IIM, SSc, SjD ADULT, OLDER_ADULTclinicaltrials@artivabio.com2902025-07-092028-012029-01
NCT07122648PN-101( MitoTherapy)Mitochondria from Allogeneic Umbilical Cord-derived Mesenchymal Stem CellsIV infusionPaean Biotechnology IncKoreaNOT YET RECRUITINGPM, DMADULT, OLDER_ADULTinfo@paeanbio.com2362025-122027-042027-04
NCT06647069DR-0201Bispecific myeloid cell engager CD20IV infusionDren Bio, now part of SanofiANZ/AUS/BS/SA/RECRUITINGSLE, CLE, SjD, DM, PM, SSc, dcSSc ADULT, OLDER_ADULTclinops@drenbio.com1362025-03-272026-122026-12
NCT07284797XmAb13676Bispecific CD19/CD3Subcutaneous InjectionXencor, Inc.AustraliaNOT YET RECRUITINGIIMADULT, OLDER_ADULT657-AIinfo@xencor.com1272026-022027-022027-02
NCT07229144OM336Bispecific BCMA/CD3Subcutaneous InjectionOuro Medicinesn/aNOT YET RECRUITINGIIM, SjDADULT, OLDER_ADULTclinical@ouromeds.com1392025-112027-062028-03
NCT06916806AZD5492 (TITAN)Trispecific T cell engager (TriTE) CD20/CD8/CD3Subcutaneous InjectionAstraZeneca/FortreaInternationalRECRUITINGSLE, IIM, RAADULT, OLDER_ADULTinformation.center@astrazeneca.com1722025-05-012027-06-222027-06-22
NCT07193810CC312Trispecific T cell engager (TriTE) CD19/CD3/CD28IV infusionCytoCares IncChinaRECRUITINGSLE, SSc, IIMADULT, OLDER_ADULTyingfeng.huang@cytocares.com162025-09-302027-09-292027-09-29
NCT06888960CC312Trispecific T cell engager (TriTE) CD19/CD3/CD28IV infusionCytoCares IncChinaRECRUITINGSLE, IIM, SSc, RA, ITP, AHAADULT, OLDER_ADULTyingfeng.huang@cytocares.com1182024-11-082026-11-082026-11-08
NCT07089121Descartes-08Autologous mRNA CAR-TIV infusionCartesian TherapeuticsUSARECRUITINGChildhood-onset SLE, AAV, MG, DM CHILD, ADULT, OLDER_ADULTtrials@cartesiantx.com1/2502026-012026-122026-12
NCT07174843BZE2204Autologous CD19/CD22/BCMA CAR-TIV infusionShanghai Cell Therapy Group Co.,LtdChinaRECRUITINGSLE, IIM,ITPADULT, OLDER_ADULTloujx@shcell.com1202025-092027-082027-12
NCT07085676HBI0101 CARTAutologous BCMA CAR-TIV infusionPolina Stepensky MD, Hadassah Medical OrganizationIsraelRECRUITINGSLE, SSc, IIM, RAADULT, OLDER_ADULTFainak@haddasah.org.il1602024-09-012026-11-012030-11-01
NCT04561557CT103A (Equecabtagene Autoleucel) +lymphodepletion with Fludarabine/ Cyclophosphamide (CARTinNS)Autologous BCMA CAR-TIV infusionTongji Hospital/Nanjing IASO Biotechnology Co., Ltd.ChinaRECRUITINGNMOSD, MG, CIDP, MS, IIM, AIE, MOGAD, POEMSADULT, OLDER_ADULTqinchuan712@126.com
chuanqin@tjh.tjmu.edu.cn		1362020-09-222027-02-222027-05-31
NCT07295847AZD0120 (AURORA)Autologous CD19/BCMA CAR-TIV infusionAstraZenecaUSA, AUS, SpainNOT YET RECRUITINGSLE, IIM, RAADULT, OLDER_ADULTinformation.center@astrazeneca.com1272025-12-162028-02-222028-02-22
NCT07086404GC012F (AZD0120) + lymphodepletionAutologous CD19/BCMA CAR-TIV infusionDaishi Tian /AstraZeneca Global R&D (China) Co., Ltd.|Gracell Biotechnologies (Shanghai) Co., Ltd.ChinaRECRUITINGRefractory IIMADULT, OLDER_ADULTtiands@tjh.tjmu.edu.cn1122025-09-152027-09-152029-09-15
NCT07072884GC012F (AZD0120) +lymphodepletion with Fludarabine/CyclophosphamideAutologous CD19/BCMA CAR-TIV infusionQiong Fu/Gracell Biotechnologies (Shanghai) Co., Ltd.n/aNOT YET RECRUITINGSSc, IIMADULT, OLDER_ADULTFuqiong5@163.com1152025-08-182027-03-312029-03-31
NCT06548607RD06-04 or RD06-05 +lymphodepletion with Fludarabine/CyclophosphamideAutologous CD19 or CD19-BCMA CAR-TIV infusionNanjing Bioheng Biotech Co., Ltd.ChinaRECRUITINGSLE, IIM, SSc, AAV, SjDADULT, OLDER_ADULTpeng.yu@bioheng.com, ming.gao@bioheng.com1202024-09-142026-07-292027-07-29
NCT07022197BAFF-R CART +lymphodepletion with Fludarabine/CyclophosphamideAutologous CAR-T BAFFIV infusionTianjin Medical University General HospitalChinaRECRUITINGCIDP, NMOSD,MG, IIMADULTqliu@tmu.edu.cn1/2272025-04-102027-12-302027-12-30
NCT06913608CLBR001 + SWI019 ( +/- lymphodepletion )Autologous Switchable CD19 CAR-T IV infusionCalibr, a division of Scripps ResearchUSANOT YET RECRUITINGSLE, SSc, IIMADULT, OLDER_ADULTabrooks@scripps.edu
zonwang@scripps.edu		1122026-022028-082028-08
NCT05869955CC-97540 Nex-T (BMS-986353) +lymphodepletion with Fludarabine/Cyclophosphamide; Tocilizumab ( Breakfree-1 )Autologous CD-19 CAR-T IV infusionJuno Therapeutics, Inc., a Bristol-Myers Squibb CompanyInternationalRECRUITINGSLE, SSc, IIM, RAADULT, OLDER_ADULTClinical.Trials@bms.com12702023-09-132028-08-292028-08-29
NCT06665256Rapcabtagene autoleucel YTB323 +lymphodepletion with Fludarabine/CyclophosphamideAutologous CD19 CAR-TIV infusionNovartis PharmaceuticalsInternationalRECRUITINGIIMADULT, OLDER_ADULTnovartis.email@novartis.com21232024-12-172029-07-172030-07-17
NCT06347718CD19 CAR-T + lymphodepletion (CASTLE)Autologous CD19 CAR-TIV infusionMiltenyi Biomedicine GmbHGermanyRECRUITINGSLE, SSc, DM, PMADULT, OLDER_ADULTgeorg.schett@uk-erlangen.de
daniela.bohr@uk-erlangen.de
1/2242023-07-172026-05-312026-05-31
NCT06685042Anti-CD19 CAR-T (CATARSIS)Autologous CD19 CAR-TIV infusionFondazione Policlinico Universitario Agostino Gemelli IRCCSItalyRECRUITINGSLE, SSc, AAV, DM, PMADULT, OLDER_ADULTmariaantonietta.dagostino@policlinicogemelli.it1/282024-11-292025-122025-12
NCT06549296RD06-04 CAR-TAutologous CD19 CAR-TIV infusionNanjing Bioheng Biotech Co., Ltd.ChinaRECRUITINGSLE, IIM, SSc, AAV, SjDADULT, OLDER_ADULTYinsonglou@163.com
13813283017@163.com		1122024-09-132026-08-012027-08-01
NCT06986018RD06-04 CAR-TAutologous CD19 CAR-TIV infusionPeking University People's HospitalChinaNOT YET RECRUITINGIIM, AAVADULT, OLDER_ADULT1i99@bjmu.edu.cn1122025-06-142025-12-312026-12-31
NCT06154252CABA-201 +lymphodepletion with Fludarabine/Cyclophosphamide (RESET-Myositis)Autologous CD19 CAR-TIV infusionCabaletta BioUSA, UKRECRUITINGAdult and Pediatric IIM6-75 yrs oldclinicaltrials@cabalettabio.com1/2242023-12-202028-072028-07
NCT07331272LUCAR-G79D +lymphodepletion with Fludarabine/CyclophosphamideAutologous CD19 CAR-T IV infusionNanjing Legend Biotech Co.ChinaNOT YET RECRUITINGSLE, IIMADULT, OLDER_ADULTSee location emails on clinicaltrials.gov1382026-01-082028-01-312030-01-31
NCT06152172KYV-101 (CARTIMMUNE)Autologous CD19 CAR-T IV infusionDavid Porter/Kyverna TherapeuticsUSAACTIVE_NOT RECRUITINGPM, DM, IMNM, dcSSc, SLE, AAVADULT, OLDER_ADULTClinicalTrialsInfo@kyvernatx.com1242024-08-052026-022026-02
NCT06298019KYV-101Autologous CD19 CAR-T IV infusionStanford University/ Kyverna TherapeuticsUSARECRUITINGDM25 Years to 72 Years oldlpanu@stanford.edu1212024-08-022027-042039-04
NCT06462144IMPT-514 +lymphodepletion with Fludarabine/Cyclophosphamide Autologous CD19/CD20 CAR-TIV infusionThe Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical SchoolChinaRECRUITINGSLE, IIM, AAVADULT, OLDER_ADULTLingyunsun2012@163.com1362024-06-132025-05-312026-10-31
NCT07038447KITE-363 +lymphodepletion with Fludarabine/CyclophosphamideAutologous Anti-CD19/CD20 CAR-TIV infusionKite, A Gilead CompanyAUS/CA/USAEnrolling by invitationSLE, LN, SSc, IIMADULT, OLDER_ADULTmedinfo@kitepharma.com1522025-07-022029-072029-07
NCT06373081CD19/CD3E CAR-T +lymphodepletion with Fludarabine/CyclophosphamideAutologous CD19/CD3 CAR-TIV infusionShanghai Changzheng HospitalChinaRECRUITINGSLE, SjD, SSc, IIM, AAV, APS ADULT, OLDER_ADULTxuhuji@smmu.edu.cnn/a62024-04-202025-04-152026-04-15
NCT06308978FT819 +lymphodepletion with Fludarabine/Cyclophosphamide BendamustineAllogenic iPSC-derived CAR-TIV infusionFate TherapeuticsUSA, UKRECRUITINGSLE, SSc IIM, AAV12-70 yrs oldclinicaltrials@fatetherapeutics.com12442024-03-282027-09-302042-09-30
NCT07339540V001-BCMAIn-vivo BCMA CAR-TInjectionTongji HospitalChinaRECRUITINGSLE, IgG4 RD, SSc, IIM, AAVADULT, OLDER_ADULTtjhdongll@163.com1452025-11-042028-10-302028-10-30
NCT06794008BCMA-CD19 CAR-T + lymphodepletionAllogenic CD19/BCMA CAR-TIV infusionPeking University People's HospitalChinaRECRUITINGSLE, IIM, SSc, AAV, Ig4RD, APS, Acquire TP, Behcet's, SjD ADULT, OLDER_ADULT569975536@qq.com2502024-12-262027-12-302027-12-31
NCT07315087QT-019CAllogenic CD19/BCMA CAR-TIV infusionInstitute of Hematology & Blood Diseases Hospital, China/Shanghai Xiniao Biotech Co., Ltd.ChinaRECRUITINGSLE, SSc, IIM, AAV, ITPADULT, OLDER_ADULTwangying1@ihcams.ac.cn1122026-01-012029-01-012029-01-18
NCT06941129UCAR T-cellAllogenic CD19/BCMA CAR-TIV infusionInstitute of Hematology & Blood Diseases Hospital, China/Shanghai Xiniao Biotech Co., Ltd.ChinaRECRUITINGSLE, SSc, IIM, AAV, CTD-TP, SLE-ITP ADULT, OLDER_ADULTwangying1@ihcams.ac.cn1122025-02-112028-02-182028-03-18
NCT06350110BH002 (BAH242)Allogenic CD19/BCMA CAR-T IV infusionEssen BiotechChinaRECRUITINGAAV, LN, SLE, SjD, GP, SSc, IIMADULT, OLDER_ADULTclinical-trials@essen-biotech.com1/2752024-07-102025-12-102025-12-28
NCT06828042 Anti-CD19 CAR-γδ T cell Allogeneic Gamma-Delta (γδ) CAR-T IV infusionPeking University People's HospitalChinaRECRUITINGSLE, SSc, SjD, AAV, IIM, APS ADULT, OLDER_ADULTzhang_xiaoying@pku.edu.cn1/292025-07-012027-12-312027-12-31
NCT06375993ADI-001 +lymphodepletion with Fludarabine/Cyclophosphamide Allogeneic Gamma-Delta (γδ) CAR-T IV infusionAdicet TherapeuticsUSARECRUITINGLN, SSc, SLE, AAV,IIM, SPS ADULT, OLDER_ADULTclinicaltrials@adicetbio.com11802024-11-102026-122027-12
NCT06980597OL-108Allogeneic Gamma-Delta (γδ) CAR-T IV infusionBeijing GoBroad Hospital / Overland TherapeuticsChinaRECRUITINGSLE, SSc, IIM, AAV ADULT, OLDER_ADULThuk@gobroadhealthcare.com1442025-062027-122028-12
NCT06379646YTS109 + lymphodepletionAllogenic CD19 TCR CAR-T IV infusionBriSTAR ImmunotechChinaRECRUITINGSLE, SSc, IIM, AAV, APS, SjD ADULT, OLDER_ADULTxuhuji@smmu.edu.cnn/a64/24/20244/21/20254/21/2026
NCT06978647YTS109 + lymphodepletionAllogenic CD19 TCR CAR-T IV infusionBriSTAR ImmunotechChinaRECRUITINGSLE, SSc, IIM, AAV, APS, RA, IG4-RD, SjD ADULT, OLDER_ADULTjian_jzhu@126.com1122025-05-192026-05-192027-05-19
NCT06316076CD19-CAR-DNT (RJMty19)  Allogenic CD19 CAR-T IV infusionRenJi Hospital/Guangdong Ruishun Biotech Co., LtdChinaRECRUITINGSLE, SSc IIM, AAVADULT, OLDER_ADULTfuqiong@renji.com1482023-10-302024-062026-06
NCT07115745BMS-986515 +lymphodepletion with Fludarabine/ Cyclophosphamide; TocilizumabAllogenic CD19 CAR-TIV infusionJuno Therapeutics, Inc., a Bristol-Myers Squibb CompanyInternationalRECRUITINGSLE, SSc, IIM, RAADULT, OLDER_ADULTClinical.Trials@bms.com11252025-09-042029-02-132030-08-16
NCT06925542CTX112 + lymphodepletionAllogenic CD19 CAR-TIV infusionCRISPR TherapeuticsDE/USARECRUITINGSLE, SSc, IIM, LNADULT, OLDER_ADULTmedicalaffairs@crisprtx.com1802025-03-102031-12-312031-12-31
NCT06686524Anti-CD19 UCAR-T cells + lymphodepletionAllogenic CD19 CAR-TIV infusionChongqing Precision Biotech Co., LtdChinaRECRUITINGDM, JDMCHILD, ADULT, OLDER_ADULTmeipinglu@zju.edu.cn1182024-11-112026-11-102027-11-10
NCT06056921CD19 CAR-T + lymphodepletionAllogenic CD19 CAR-TIV infusionChongqing Precision Biotech Co., LtdChinaRECRUITINGSLE, SSc, DM, AAV ADULT, OLDER_ADULT1315710223@qq.com1242023-08-312025-12-312026-08-31
NCT06569472CD19 CAR-T + lymphodepletionAllogenic CD19 CAR-TIV infusionChongqing Precision Biotech Co., LtdChinaRECRUITINGJDMCHILDmeipinglu@zju.edu.cn1102024-07-022027-07-312028-07-31
NCT07184450BCMA/CD70 CAR-T + lymphodepletionAllogenic BCMA/CD70 CAR-TIV infusionChongqing Precision Biotech Co., LtdChinaRECRUITINGJDM, SSc, SjD, paJIACHILD, ADULT, OLDER_ADULTmeipinglu@zju.edu.cn1112025-09-012026-03-302028-09-30
NCT07085104ALLO-329 +/- Cyclophosphamide (RESOLUTION)Allogenic CD19/CD70 CAR-TIV infusionAllogene TherapeuticsUSARECRUITINGSLE, SSc, IIM, LNADULT, OLDER_ADULTclinicaltrials@allogene.com1542025-092028-022032-10
NCT06614270Anti-CD19 IL-10/IL15 CAR-NKAllogenic CD19 IL-10/​IL15 Cord Blood-derived CAR-NKIV infusionSecond Affiliated Hospital, School of Medicine, Zhejiang UniversityChinaRECRUITINGSSc, AAV, IIM, SjD, APS, SLE ADULT, OLDER_ADULT jingxue@zju.edu.cnn/a152025-01-062026-01-062027-01-06
NCT06733935NKX019 +lymphodepletion with Fludarabine/Cyclophosphamide (Ntrust2)Allogenic CD19 CAR-NKIV infusionNkarta, Inc.USA/Puerto RicoRECRUITINGSSc, IIM, AAV ADULT, OLDER_ADULTclinicaltrials@nkartatx.com1/21442024-11-042028-102028-10
NCT06255028CNTY-101 (CALiPSO-1)Allogenic CD19 CAR-NKIV infusionCentury Therapeutics, Inc.USAACTIVE_NOT RECRUITINGSLE, LN, IIM, dcSSc CHILD, ADULT, OLDER_ADULTinfo@centurytx.com162025-02-062028-082028-08
NCT06970951UTAA91 Allogenic CD19/PD1 CAR-Vδ1T IV infusionPersonGen BioTherapeutics (Suzhou) Co., Ltd.ChinaNOT YET RECRUITINGSLE, RA, SjD, IIM, SSc ADULT, OLDER_ADULTnjwujian@163.com1152025-05-182026-06-302027-04-30
NCT06361745UTAA09Allogenic CD19 CAR-gdT IV infusionPersonGen BioTherapeutics (Suzhou) Co., Ltd.ChinaRECRUITINGSLE, SjD, IIM, SSc, Ig4RD ADULT, OLDER_ADULTyinsonglou@163.comn/a102024-04-022024-12-012025-03-01
NCT06417398UTAA09Allogenic CD19 CAR-gdT IV infusionPersonGen BioTherapeutics (Suzhou) Co., Ltd.ChinaNOT YET RECRUITINGSLE, IIM, SSc, SjD, RA, ITP, PBC ADULT, OLDER_ADULTnjwujian@163.com1102024-05-142024-12-012025-05-01

Abbreviations

AAV: Ant-neutrophil cytoplasmic antibody (ANCA) associated vasculitis

AHA: Autoimmune Hemolytic Anemia

APS: Antiphospholipid Syndrome

ASyS: Anti-Synthetase Syndrome

BCMA: B-cell Maturation Antigen

BP: Bullous Pemphigus

CAR-T: Chimeric Antigen Receptor T-cell

CAR-NK: Chimeric Antigen Receptor Natural Killer-cell

CIDP: Chronic Inflammatory Demyelinating Polyneuropathy

CLE: Cutaneous Lupus Erythematosus

dcSSC: diffuse cutaneous Systemic Sclerosis

DM: Dermatomyositis
JDM: Juvenile Dermatomyositis

FcRn: Neonatal fragment crystallizable receptor

GLP: Glucagon like peptide

JAK: Janus Kinase

KLRG1: Killer cell lectin-like receptor G1

IBM: Inclusion Body Myositis

IFN: Interferon

IIM: Idiopathic Inflammatory Myopathies

IMNM: Immune-mediated Necrotising Myopathy
ITP: Idiopathic Thrombocytopenia

IV: Intravenous

LN: Lupus Nephritis

mAb: monoclonal antibody

MA-ILD: Myositis Associated Interstitial Lung Disease

MG: Myasthenia Gravis

mTOR: mammalian Target of Rapamycin

NMOSD: Neuromyelitis Optica Spectrum of Disorders

PBC: Primary Biliary Cholangitis

PM: Polymyositis

RA: Rheumatoid Arthritis

SC: Subcutaneous

SLE: Systemic Lupus Erythematosus

SjD: Sjögren’s Disease

SPS: Stiff Person Syndrome

TYK: Tyrosine Kinase